COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated [...]
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision [...]
Iantrek Advances New AlloSpan™ Canal into U.S. Site Evaluations, Expanding Its Bio-Interventional Platform
31/03/2026
Controlled early clinical adoption begins across select U.S. centers as Iantrek accelerates toward commercialization of its next-generation canal-based restoration technology WHITE PLAINS, N.Y., March 31, 2026 (GLOBE [...]
Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results
31/03/2026
Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science [...]
Vantive Presents New Data at WCN on How Coordinated Care Ecosystems Can Expand Home-Based Peritoneal Dialysis Access and Improve Patient Outcomes
31/03/2026
Nephroprotection and early intervention support more planned dialysis starts, improved patient outcomes and increased use of home therapies, according to new studies. Real-world studies also evaluate a unique care [...]
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
31/03/2026
Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: [...]
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03/2026
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS [...]
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
31/03/2026
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of [...]
QHSLab (OTCQB:USAQ) Reports Strong Fiscal 2025 Results with Revenue Growth, Expanding Margins, and Significant Balance Sheet Improvement
31/03/2026
Integrated Service Program Growth Drives Revenue Expansion and Margin Improvement Delivering Improved Profitability and Debt Reduction in Fiscal 2025 Operational Momentum and Balance Sheet Restructuring Position Company [...]
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
31/03/2026
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE [...]
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
31/03/2026
Enhances Intellectual Property Portfolio and Strengthens the Potential for Neridronate Exclusivity through 2045 IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the [...]
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., [...]
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
31/03/2026
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider [...]
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31/03/2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026 with first-in- [...]
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026
Amazon customers can now discover and enroll in Berry Street's evidence-based nutrition care for weight loss, 30+ conditions NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Berry Street , an AI-powered nutrition therapy [...]
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026
Model estimates SUBLOCADE ® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior [...]
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques
31/03/2026
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques Paris, France et Menlo Park, USA (31 mars 2026) – EssilorLuxottica et Meta annoncent l'expansion de leur [...]
EssilorLuxottica and Meta Expand AI Glasses Portfolio with Ray-Ban Meta Optics Styles
31/03/2026
EssilorLuxottica and Meta Expand AI Glasses Portfolio with Ray-Ban Meta Optics Styles Paris, France and Menlo Park, CA (31 March 2026) – EssilorLuxottica and Meta announce the expansion of their AI glasses portfolio [...]
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026
Alira Health’s annual CDMO medtech report highlights growth, consolidation, and capability expansion; market projected to reach $143.6B by 2030 at an 8.3% CAGR FRAMINGHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Alira [...]

Pages